Tech Company Financing Transactions
Atox Bio Funding Round
Private investors participated in a $33 million funding round for Atox Bio. The round was announced by the company on 5/1/2019.
Transaction Overview
Company Name
Announced On
5/1/2019
Transaction Type
Venture Equity
Amount
$33,041,798
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 15 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Vilcom Ctr. Dr. 230
Chapel Hill, NC 27514
USA
Chapel Hill, NC 27514
USA
Phone
Website
Email Address
Not Recorded
Overview
Atox Bio is a clinical stage biotechnology company that develops therapeutics for diseases mediated by a deregulated inflammatory response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Teleman
Chief Financial Officer
Esti Hayun
Chief Medical Officer
Wayne Dankner
Chief Scientific Officer
Raymond Kaempfer
Vice President
Corinne Zollmann
VP - Bus. Development
Robert Greif
VP - R & D
Anat Shirvan
VP - Regulatory Affairs
Meir Batito
Browse more venture capital transactions:
Prev: 5/1/2019: Allganize venture capital transaction
Next: 5/1/2019: Duco Advisors venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs